Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.
Tournilhac O, Cazin B, Leprètre S, Diviné M, Maloum K, Delmer A, Grosbois B, Feugier P, Maloisel F, Villard F, Villemagne B, Bastit D, Belhadj K, Azar N, Michallet M, Manhès G, Travade P. Tournilhac O, et al. Among authors: cazin b. Blood. 2004 Jan 1;103(1):363-5. doi: 10.1182/blood-2003-05-1449. Epub 2003 Sep 11. Blood. 2004. PMID: 12969985 Free article.
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Lepretre S, et al. Among authors: cazin b. Blood. 2012 May 31;119(22):5104-10. doi: 10.1182/blood-2011-07-365437. Epub 2012 Feb 14. Blood. 2012. PMID: 22337714 Free article. Clinical Trial.
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C; French Cooperative Group on Chronic Lymphocytic Leukemia. Leporrier M, et al. Among authors: cazin b. Blood. 2001 Oct 15;98(8):2319-25. doi: 10.1182/blood.v98.8.2319. Blood. 2001. PMID: 11588025 Free article. Clinical Trial.
Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.
Fornecker LM, Aurran-Schleinitz T, Michallet AS, Cazin B, Guieze R, Dilhuydy MS, Zini JM, Tomowiak C, Lepretre S, Cymbalista F, Brion A, Feugier P, Delmer A, Leblond V, Ysebaert L. Fornecker LM, et al. Among authors: cazin b. Am J Hematol. 2015 Jun;90(6):511-4. doi: 10.1002/ajh.23999. Epub 2015 Apr 1. Am J Hematol. 2015. PMID: 25752923 Free article. Clinical Trial.
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.
Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V. Dartigeas C, et al. Among authors: cazin b. Leuk Lymphoma. 2016 Feb;57(2):328-334. doi: 10.3109/10428194.2015.1063139. Epub 2015 Sep 28. Leuk Lymphoma. 2016. PMID: 26140301
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P. Meunier G, et al. Among authors: cazin b. Hematol Oncol. 2017 Dec;35(4):671-678. doi: 10.1002/hon.2370. Epub 2016 Nov 22. Hematol Oncol. 2017. PMID: 27878835
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S. Feugier P, et al. Among authors: cazin b. Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. Haematologica. 2018. PMID: 29545348 Free PMC article. No abstract available.
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, Cymbalista F; French Innovative Leukemia Organization (FILO). Letestu R, et al. Leukemia. 2021 Jun;35(6):1597-1609. doi: 10.1038/s41375-020-01009-z. Epub 2020 Sep 15. Leukemia. 2021. PMID: 32934355
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.
Cazin B, Divine M, Leprêtre S, Travade P, Tournilhac O, Delmer A, Jaubert J, Feugier P, Dreyfus B, Mahé B, Grosbois B, Maloisel F, Eghbali H, Dumontet C, Bénichou J, Guibon O, Leleu X, Leporrier M, Maloum K. Cazin B, et al. Br J Haematol. 2008 Oct;143(1):54-9. doi: 10.1111/j.1365-2141.2008.07309.x. Epub 2008 Aug 15. Br J Haematol. 2008. PMID: 18710390 Free article. Clinical Trial.
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
Maloum K, Settegrana C, Chapiro E, Cazin B, Leprêtre S, Delmer A, Leporrier M, Dreyfus B, Tournilhac O, Mahe B, Nguyen-Khac F, Lesty C, Davi F, Merle-Béral H. Maloum K, et al. Among authors: cazin b. Ann Hematol. 2009 Dec;88(12):1215-21. doi: 10.1007/s00277-009-0742-6. Epub 2009 Apr 2. Ann Hematol. 2009. PMID: 19340428
46 results